to focus entire to by the successful our of our our XXXX bringing continued and earnings quarter to thanking a for for call. effort third application. critical Good to support really Kelly. close. joining thank like start and dedication proud quarter customers' Thanks, off you morning, their their life third I'd I'm in team tremendous
from shipments strong above We device prior of year remaining macro third revenue a our third XX% environment, in Army customers. revenue from was team quarter period increasing business delivered is operating the and and going during new and other $XX.X and U.S. to About over XX% with quarter are million. was the XX% challenging beyond. growth the We
begun are into a cycles results in While funnel our have our the to see third and performance, we summer purchasing fall. we quarter slowdown months prolonged with pleased over the and year-to-date with
is serve. the We due adverse factors we markets this largely impact to across macroeconomic of believe the
We expect next the couple continue and quarters. impairment to headwinds these over of
Given year be this the expect impact, the now million, annual million revenue growth of full of to to we $XX midpoint in range. XXXX of representing at XX% the range $XX
discussed test seen on conversion. at full need achieve few As ever. required for firmly robust trials last opportunities the in as near-term opportunity to larger point the previous our would pressure, rapid protracted and pilots a our cycles to to of believe we've strong as analytics we and guidance, call, be earnings this enterprise progression handheld of year Despite
XXXX, customers from our Police combat hear serving breadth spanning and provide Critical truly user was together It than was This University, government, of mass to Department. Mass Boehringer-Ingelheim, positive and the Clemson the including and our to MIT, September, Investigation robust of of impact heard in California applications. their Bureau bio-therapeutics is Fresno, reinforced Opioid point academia at XXX Criminal view platforms covered virtually product We the the spec meeting inspiring industry advance rapid both that having information need. the full using our and share in Ohio technology crisis. event success person and brought more and and to customers, their devices our to actionable at which This
adoption. areas of the Now driving Starting for X to on our drive with to over we focus progress objective our provide across brief I'd growth a term. update the customer set XXXX like longer first
fuel and more see the Metabolomics underlying biopharmaceutical increase process more control of long-term for steady we continuing advanced For are therapeutics. proteomics and which the need to our industry's demand in desktops, for Research, growth. The all
However, gene space. for and development technology demand in application, our macro shift devices, is cell where desktop the begun the particularly near-term process support has therapy preclinical the some environment flow being to in adopted to
Medicine advanced and has already several issued report of therapies, its Regenerative gene XXXX year that therapies cell the first decisions XXXX noted on The late half regulatory in which record for track on new and recently been Alliance therapies other approval with a XXXX for XXXX.
years. XXXX number globally continue see desktop, we of trials the customers. investment of after a ongoing from X and clinical between end have even fairly and However, from to decreased existing orders record-breaking XX% by Across slowed levels split new the our
its during application. in the the a with our to September throughput see exchange in ZIP therapy additional chemistry CAR-T a REBEL device's traction of continue Genentech pharma quarter analytical at concurred ordering noted fourth fourth unit published researchers companies chip paper the peptide high their device, second companies some a of even With several high units Genentech XX sensitivity quantify in device, these in in With cell top device. ability we to a or the and with and
Overall, enterprise we foothold term. continue believe accounts, work and broader adoption drive the to and accounts penetrate a acceptance which will in new to radiate over strategy then and we penetrate our that long create radiate across these
a of abating. last Statistics expectancy Turning that announced for the August, of Center crisis lowest to handhelds. XXXX. decreased level CDC no our its The In now shows to Opioid division the since life National year U.S. Health signs
While drug. of and of comprised be COVID-XX highlighted decline, primary the crisis several was another drug to recent on This was ADHD the sourcing of counterfeits the news continues the adoption. of There driver In crisis. treat other dangers to of noted these unintentional mainly major the overdoses. leading are September, cause street reports a as contain Fentanyl Adderall and customer severity report death, the the cause of shortage new a to used highlight ongoing
Tandifentanal Adderall the than noting methamphetamine. confirmed forms shortage, March resemble sees sidewalk also or FDA containing young counterfeit truck. The Rhode Fentanyl, rainbow generic not in powder authority of of that has available target may children. that advisory XXX,XXX blocks Rainbow until pills, September, in brightly The XXXX. has used multiple including DA an issued several DEA be Fentanyl, and seized to the forms Adderall Also And Island, more warning DAA known as colored
Finally, in Police the Australian Border detected announced in festival seizure hitting than the X the Australia, the shipment Force Federal of more potential preventing doses in August, largest drug street. Australian the of the million legal
it Fentanyl are global U.S., While evidence the is deadliest a and that crisis. the becoming more seeing noted DA has threat drug facing we of the more
continue jails for spread drug. of first A point case the dangerous chemical and combat need statistics sobering alarming workers detection have need in to point news highly in the the increase to at MX-XXX highlight drugs These Corrections and orders year in device legal correspondence New trace the to reports coming at frontline Department order facilities. and from throughout other is the England. based for responders of in another with a personal in correctional several devices third of regional mail county quarter the X from see for We've
a MX modules trials previously the order pipeline enterprise compared In of drive Army, handheld fleet with testing, As to of for XX pilot an for Aero adoption receiving $X account, we the devices. U.S. our built programs noted, million existing the of and expanded quarter, enterprise we devices. their in third
to detect module its enables Once identify hazards Aero users vapor last and the year, kind monitor, first safely. aerosol quickly and of and
accelerating commercialization. Turning to our objective, second
reaching XXX uncertain That amidst worldwide employees the be goal end the commercial macro and quarter, backdrop. of across this expansion to of over now team planned we all continue thoughtful we have of our our close to third reviewing said, are As XX members. commercial regions
of advancing penetrate additional and and product platform's objective, developing our order market. to for increase third Turning integration areas assay to to analytics, of use our addressable accessories our unlock we consistent continue and our through data customers releases in portfolio, our to capabilities
underlying primarily we a multi-agency of highly the to water the on are state is illegal in to conduct site where the illegal grows a to often to crime. central to detect waiting is illegal grow our and wildlife particularly used had safe send issue testing For lab, weeks a its aim several This of method the effort prosecuting people. pesticides. and pesticide expanded illegal personnel These program. eradication handhelds, be of samples capability federal federal conduct land, will no marijuana marijuana posing reliable our California, a and and environmental The environment, device to critical being seasonal the now expanding toxic threat sources, safe and had pesticides remediation. MXXXX X marijuana to with at labor year-round Previously, site
and the MX-XXX a of Agency the Department to this January Service In to the the pesticides. research United States detect year, States United of collaboration these extend of of illegal capabilities Forest Agriculture we with announced
additional our kit and introduced spent refine and to our tips to quantification for meet which provided calibration REBEL, we an X.X continue For improved customer Version for and analysis results. media of accuracy desktops, enhanced needs. We develop
to of boundaries kit first are of in released We XXXX REBEL developing performance immune specific a of analytical be set for most in focused measured the acids that commonly applications. the another pushes half
TRACE to our of further extremely In well team online our regard Analytics R&D with team TRACE efforts. in with is integrating are the pleased August, acquisition how to we our development
development Technology, our online a to may you and us more will and TRACE which recall, As our fluidic acquisition addition with central is help micro Acceptor color of of and total technology and the unlock Bioreactor sampling has us cell Biosensor of provided all chain been at proven Their research reusable micro-bio and in single-use configuration to large-scale addressable production. culture market. technology and levels mammalian from bioprocess our fermentation
a now cell-free, our of no lactate of At in presented and our Trace Analytics user lab, Founder sterile which prep process glucose safe the required. Head includes meeting, Bio-analytics of automated sampling or the development with control R&D Wolfgang volume Künnecke, benefits in and
to of this platform. existing we products to technology focus our releasing we have expand year capabilities main and plan noted, XXXX, the shift our upon our build to focus reach of X devices. been the new In has our As
we early We in as are share XXXX. impactful to more details next year to them excited be expect
and biopharma broadening to advanced platform therapies entire bio-analytics understand workflow. the process more quality on critical as fourth pipeline, product our impact attributes Turning during manufacturers parameters critical objective, our development to need process identify and bio-manufacturing the their and enter
this well meet to need. Our positioned devices are
workflow. the continue industry of highlighted and institutions academic We months. key at the providing accelerate a been over rapid with has robust number bio-therapeutic to value few that and demonstrate technology value This partners events our in collaborate manufacturers past industry enables of to information to
Process improved U.K. culture for the Center cell cell the to inform Independent the Innovation feeding strategies in growth. with Organization media demonstrated at-line analysis and Innovation value collaboration of Our for
to resulting CPI accumulation up process to demonstrating in the design data in a poster International more and a the presented conduct REBEL our this metabolite Pharma experiment times. webinar CE engineers were as amino nutrients, Tier by a from in value toxic and as at analysis in key and in from increase enabling reduction our hosted REBEL significant reduction data recently by Magazine such acid engineers results BioPharma an Independent Symposium of real-time process proposition, XX% These optimize is analyzers use adoption a to broader mid-September. regularly.
benefit no of ZipChip in high comparable molecules. several Oligos, much recombinant posters Protein metric. of the other faster the for LCMS method presented and case AAVs were resolution sensitivity including and at our There Cash our Oligonucleotides, Scientific Bio-Techne, high including CE Fisher And Cogen, costs minimal in of and ZipChip charge with in several to reagents. varying posters and separations sample peptide Farm Thermo Conference, these included Mass volumes. Spec Symposium pairing by mapping characterizing of device the but collaborators use applications, small analysis harsh These the highlighted highlighted
biotech At high-resolution gave characterization spec-based the International show, a company complex at-line the presented Hopkins Wheat, bioprocess a the and presentation development on biopharmaceuticals ZipChip separations, at power modeling. Biotech part Bioprocess Boston scientist while sample at labs workflows mass prep a of to to perform leveraging noted show, minimizing University immunoacid Also from with principal the capability on in REBEL burden. enable Cypogen, John collaborators our measurement of
at meeting, product Boehringer-Ingelheim city from our very and high-sense antibodies. Finally, separations towed fast quality Oligonucleotide user characterizing monoclonal scientists attributes in ZipChip the in
process. monitor value underscored and recombinant rapidly consumption to researchers ability and the nutrient cells of perfusion producing in REBEL's MIT AAV profile their Additionally,
robust customers to product attributes multiple delighted to of product parameters, collaborators devices ultimately quality. our are and to improved highlight characterize desktop their leads which the control key hear biopharma and We value efficiency process and quality
mass to for emerging metabolomics turning objective, longest-term opportunities. an and address accelerating Omaxe and to finally, we workflows see clear laying And our need proteomics a spec-based Foundation,
support angle. healthy along affected future to continue technology metabolite of used broker research in identification. institutions areas confidence and and workflow Omaxe Researchers publications, cadence human research domain. Type signaling and mass its levels research the We versus proteomics minutes, and In of academic fast to launches pancreatic with time and focused within molecule the metabolomics separation to X on the paper with a foster X characterizing of partners and in product academic journal, spectrometer diabetes ZipChip cell-to-cell high with a noted specific
we As facing month, advancing leaders emerging Proteomic metabolomic Advisory Scientific research chips we provided to are meeting where a previously proteomic hosted and of microfluidic address Board, and and the guidance opportunities. shared, Omaxe feedback our on opinion efforts. our key our of development direction Last
Board pre-concentration market. emerging continued from of Our to about were feedback peptide our and low members enthusiastic Scientific platform, requirements on throughput proteomics Advisory input the development robustness ZipChip on-chip address providing
to group efforts. thought development advance our of their leaders fortunate this insights remarkable are as We have share we
of laboratory centralized our point bring by to our we break summary, customers of mass-spec to the remain encouraged it In confines providing is the need. platform a to out the value and of technology
to face our some more technology customers, base new applications. audiences, and our our on broader expanding for macro we focus users continue accessible even and we which serving open stores While making pressure, user to near-term
now I'll for that, the financials. call With our over details turn on to more Joe
